![](/wp-content/uploads/2019/06/fenix-group-announcement.png)
$599
Zealand Q2 ’18 earnings summary
Zealand hosted its Q2 ’18 earnings call (press release) and provided updates on its diabetes portfolio including dasiglucagon, which is being studied for three distinct indications (hypoglycemia rescue, use in a dual-hormone pump, and congenital hyperinsulinism).